Stay updated on Pembrolizumab in cSCC: Recurrent/Metastatic Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab in cSCC: Recurrent/Metastatic Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab in cSCC: Recurrent/Metastatic Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    Expanded location list and a new last update date, while enrollment remains 159 and there are no changes to primary outcomes or eligibility criteria. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.3%
    Check dated 2025-11-03T01:32:58.000Z thumbnail image
  2. Check
    9 days ago
    No Change Detected
  3. Check
    30 days ago
    Change Detected
    Summary
    The page now includes an operating-status notice and a version update to v3.2.0, while removing the previous v3.1.0 reference.
    Difference
    2%
    Check dated 2025-10-05T10:34:09.000Z thumbnail image
  4. Check
    38 days ago
    Change Detected
    Summary
    The page updates the revision from v3.0.2 to v3.1.0, indicating a new version is available. If there is additional content tied to the release, it isn’t shown here.
    Difference
    0.1%
    Check dated 2025-09-28T03:22:55.000Z thumbnail image
  5. Check
    52 days ago
    Change Detected
    Summary
    The page now shows Revision: v3.0.2, replacing v3.0.1, and the 'Back to Top' element has been removed.
    Difference
    0.1%
    Check dated 2025-09-13T17:40:07.000Z thumbnail image
  6. Check
    59 days ago
    Change Detected
    Summary
    The web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes in core content, pricing, or availability.
    Difference
    0.1%
    Check dated 2025-09-06T15:20:03.000Z thumbnail image
  7. Check
    66 days ago
    Change Detected
    Summary
    The web page has undergone significant updates, including the addition of specific facility names and locations, as well as a new version revision. Notably, the names of locations and the drug pembrolizumab have been standardized in their presentation.
    Difference
    5%
    Check dated 2025-08-30T11:58:17.000Z thumbnail image

Stay in the know with updates to Pembrolizumab in cSCC: Recurrent/Metastatic Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in cSCC: Recurrent/Metastatic Clinical Trial page.